Replies to post #228077 on Biotech Values

[DewDiligence]

ENTA—Re: hMPV

This excerpt from ENTA’s 1/9/20 PR (#msg-153206240) is being discussed on the JPM webcast:

We are also introducing today our newest program, which is for treatment of hMPV, a pathogen identified in 2001 that causes upper and lower respiratory tract infections in young children and the elderly, as well as COPD, asthma, and immunocompromised patients.

“hMPV” is human metapneumovirus, which is similar to RSV and has no approved vaccines or treatments.

ENTA's hMPV program is in the lead-optimization stage.